CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption by Harper, J. et al.
1Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA. 2HIV Discovery Performance 
Unit, GlaxoSmithKline, Research Triangle Park, NC, USA. 3UNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel 
Hill, Chapel Hill, NC, USA. 4Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA. 5Perelman School of Medicine, 
University of Pennsylvania, Philadelphia, PA, USA. 6HIV Discovery, ViiV Healthcare, Research Triangle Park, NC, USA. 7Division of Animal Resources, 
Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA. 8Biopharm Innovation, GlaxoSmithKline, Stevenage, UK. 9AIDS and Cancer 
Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 10Department of Pathology and Laboratory Medicine, Emory 
University School of Medicine, Atlanta, GA, USA. 11Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA. 
✉e-mail: mirko.paiardini@emory.edu
The primary human immunodeficiency virus (HIV) reservoir 
is composed of resting memory CD4+ T  cells, which often 
express the immune checkpoint receptors programmed cell 
death protein 1 (PD-1) and cytotoxic T lymphocyte-associated 
protein 4 (CTLA-4), which limit T cell activation via synergis-
tic mechanisms. Using simian immunodeficiency virus (SIV)-
infected, long-term antiretroviral therapy (ART)-treated 
rhesus macaques, we demonstrate that PD-1, CTLA-4 and 
dual CTLA-4/PD-1 immune checkpoint blockade using mono-
clonal antibodies is well tolerated, with evidence of bioactiv-
ity in blood and lymph nodes. Dual blockade was remarkably 
more effective than PD-1 blockade alone in enhancing T cell 
cycling and differentiation, expanding effector-memory 
T  cells and inducing robust viral reactivation in plasma and 
peripheral blood mononuclear cells. In lymph nodes, dual 
CTLA-4/PD-1 blockade, but not PD-1 alone, decreased the 
total and intact SIV-DNA in CD4+ T cells, and SIV-DNA and 
SIV-RNA in B cell follicles, a major site of viral persistence 
during ART. None of the tested interventions enhanced SIV-
specific CD8+ T  cell responses during ART or viral control 
after ART interruption. Thus, despite CTLA-4/PD-1 blockade 
inducing robust latency reversal and reducing total levels of 
integrated virus, the degree of reservoir clearance was still 
insufficient to achieve viral control. These results suggest 
that immune checkpoint blockade regimens targeting PD-1 
and/or CTLA-4, if performed in people living with HIV with 
sustained aviremia, are unlikely to induce HIV remission in 
the absence of additional interventions.
Due to the complexity and diversity of the CD4+ T cell compart-
ment, identification of the specific subsets that preferentially har-
bor replication-competent simian immunodeficiency virus/human 
immunodeficiency virus (SIV/HIV) under long-term antiretroviral 
therapy (ART) is considered a critical step to facilitate the design of 
therapeutics aimed at eliminating persistent viral reservoirs. Recent 
studies reported high levels of viral DNA in memory CD4+ T cells 
expressing immune checkpoint receptors (ICRs)1–3, including pro-
grammed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-
associated protein 4 (CTLA-4), which define a quiescent population 
with impaired effector function enforced by distinct, synergistic 
pathways4,5. Lymph node (LN) CD4+PD-1+ T  cells, in particular 
follicular helper T cells (TFH) in the B cell follicle (BCF), represent 
a major potential source of inducible, replication-competent virus 
in ART-treated, HIV-infected subjects2,6. Chronic viral infection 
enhances PD-1 expression on HIV-specific CD8+ T  cells, which 
exhibit impaired cytokine production upon antigen stimulation, 
diminished proliferative capacity, abnormal cellular differentiation 
and exhaustion7,8. In rhesus macaques (RMs) we have demonstrated 
that, in addition to PD-1+ TFH cells, memory CD4+CTLA-4+PD-1− 
T  cells harbor replication-competent SIV, phenotypically overlap 
with regulatory T cells (TREGs), reside in the lymphoid T cell zone 
(TCZ) and increase their contribution to the viral reservoir over 
time with ART1. Collectively, these observations provide a strong 
rationale for targeting CTLA-4/PD-1-expressing T  cells with the 
aim of relieving (‘shock’) the quiescent transcriptional state that 
promotes viral latency while also restoring immune effector func-
tions that may result in viral clearance (‘kill’).
As a proof of concept in ART-treated, HIV-infected patients, 
the sequential in  vivo blockade of CTLA-49 and PD-110 yielded 
greatly expanded levels of cell-associated HIV-RNA in a patient 
with metastatic melanoma; furthermore, PD-1 blockade produced 
significant declines in HIV-DNA in a patient with relapsed non-
small-cell lung cancer11, but has proven highly variable10,12,13. In 
viremic, SIV-infected RMs (without ART or with viremia incom-
pletely suppressed by ART), CTLA-4 blockade has produced incon-
sistent results on viral reactivation and on SIV-specific CD8+ T cell 
responses14,15. Similarly, PD-1 blockade decreased set-point viremia 
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and improved SIV-specific T cell responses during chronic infec-
tion16, with only a modest effect in enhancing antiviral responses 
during short-term ART17 and no impact on long-term ART18. In this 
study, we examine the immunologic and virologic effects and the 
therapeutic potential of PD-1 and CTLA-4 blockade in SIV-infected 
RMs treated with long-term ART.
Results
CTLA-4 and PD-1 blockade is biologically active in SIV-infected, 
ART-treated RMs. Thirty-four RMs were intravenously infected 
with SIVmac239 (Fig. 1a); RM RFf16 was euthanized at day 25 post-
infection (d25 p.i.) related to rapid AIDS progression. Set-point viral 
loads ranged between 2.5 × 105 and 8.4 × 107 copies per ml, with one 
outlier (RKt16 at 8 × 102 copies per ml). At d60 p.i. ART consisting 
of tenofovir (TDF), dolutegravir (DTG) and emtricitabine (FTC) 
was initiated and maintained for up to 13.5 months. Viremia was 
controlled to undetectable levels (<60 copies per ml) with transient 
blips observed in RAi16, ROp16 and RZl16 RMs (Extended Data 
Figs. 1 and 2a). RMs were stratified into treatment groups based on 
acute (‘peak’) and set-point (‘chronic’ at ART initiation) viral load, 
duration of virologic suppression, MHC haplotype (6 Mamu-A*01+) 
and a lack of naturally arising, cross-reactive anti-drug antibodies 
(ADAs) against the therapeutic immune checkpoint blockade (ICB) 
monoclonal antibodies (mAb) in plasma (Supplementary Fig. 1 and 
Supplementary Table 1). Four doses of mAbs targeting PD-1 and/
or CTLA-4 were infused weekly. RMs had an average of 181.4 ± 4.9 
days of virologic suppression, ensuring that immune interventions 
and SIV-DNA reservoir measurements were not conducted in the 
setting of overt viral replication. Two weeks after mAb administra-
tions, all animals underwent ART analytical therapy interruption 
(ATI) and were followed for seven months.
In non-human primates (NHPs), repeated doses of ipilimumab, 
a humanized immunoglobulin-G1 (IgG1) anti-CTLA-4 mAb, did 
not induce ADAs14,15; however, nivolumab, a humanized IgG4 anti-
PD-1 mAb, was immunogenic with blunted proliferative responses 
upon serial administration19. To improve the effective dosing dura-
tion, an IgG4 nivolumab-biosimilar anti-PD-1 was rhesusized with 
human variable domains and macaque constant regions (αPD-1, 
n = 6) and further formulated as a bispecific IgG1 mAbdAb with 
ipilimumab-biosimilar anti-CTLA-4 mAb (BsAb, n = 8). Additional 
treatment groups include ipilimumab-biosimilar anti-CTLA-4 mAb 
(αCTLA-4, n = 6) with Fc-γ binding activity, anti-CTLA-4 mAb in 
conjunction with an anti-PD-1 mAb (combined blockade, n = 7) 
and a control mAbdAb (VHDUM) that lacks known specificity 
(control, n = 6; Extended Data Fig. 2b).
Infusion resulted in sustained plasma concentrations of all mAbs 
through four cycles of administration (Extended Data Fig. 3a), but 
the BsAb formulation had faster in  vivo clearance. Few animals 
showed the emergence of ADAs, which were associated with a 
reduction in plasma mAb concentrations (Extended Data Fig. 3b). 
Target receptor engagement was remarkably high, both for memory 
(CD95+) CD4+ and CD8+ T  cells, as confirmed via PD-1 occu-
pancy using the EH12.2H7 detection antibody in peripheral 
blood mononuclear cells (PBMCs; Fig. 1b–d and Supplementary 
Fig. 2) and LN biopsies (Fig. 1e–g); however, BsAb treatment was 
associated with reduced PD-1 occupancy by d21 post-treatment 
(p.t.), consistent with its pharmacokinetics (Extended Data Fig. 3a). 
PD-1 occupancy was observed within LN-resident TFH cells 
(PD-1hiCXCR5+CD95+CD4+ T cells), indicative of follicular distri-
bution, without impacting follicle homing as measured by CXCR5 
expression (Fig. 1h, data not shown)20. Thus, the tested mAbs 
engage their cognate receptor in blood and LN, whereas the BsAb 
fail to improve plasma concentrations or target engagement as com-
pared to combined blockade.
Mono- and dual-ICB were well tolerated without evidence of 
treatment-induced clinical pathology, acute inflammatory reactions, 
cytokine release syndrome, abnormal blood counts, nephrotoxic-
ity or hepatotoxicity (Supplementary Table 2 and Supplementary 
Fig. 3a–c). None of the treatment regimens impacted the number 
of circulating neutrophils or eosinophils, while αPD-1 exhibited 
a transient increase in the number of monocytes (Supplementary 
Fig. 3d). Immunophenotypic analysis of unoccupied PD-1 epit-
opes (clone 913429) in LN demonstrated that PD-1 blockade did 
not result in an expansion or contraction of PD-1+ T cells (data not 
shown) or TFH (Supplementary Fig. 4a,b). CTLA-4 blockade, par-
ticularly in combination with PD-1 blockade, was associated with 
an expansion of CTLA-4+ memory CD4+ T  cells in PBMCs and 
LN (Supplementary Fig. 4c,d), and significantly increased levels of 
CD4+ regulatory T cells (TREGs; CD25+CD127−FoxP3+) in PB and LN 
(Fig. 1i, j). Furthermore, the magnitude of the CD4+ TREG expansion 
at day 28 p.t. was directly correlated with the plasma concentration 
of CTLA-4 blocking mAbs (r = 0.5692, P = 0.0434; Supplementary 
Fig. 4e). Therefore, dual CTLA-4/PD-1 blockade was biologically 
active and demonstrated an acceptable safety profile in ART-treated, 
SIV-infected RMs.
T  cell proliferative and effector responses are synergistically 
improved by dual CTLA-4/PD-1 blockade. As ICB was biologi-
cally active, we determined how those interventions impacted the 
levels of proliferating T  cells. Blockade of CTLA-4, particularly 
when combined with PD-1 blockade, was remarkably effective 
in expanding the number of circulating memory CD4+ T  cells 
expressing Ki-67. Specifically, combined blockade induced a large 
increase in the number of PB memory CD4+Ki-67+ T cells (from 
106.3 ± 9.263 to 642.6 ± 80.04 at d7 p.t.; Fig. 2a,b) and PB memory 
CD8+Ki-67+ T cells (from 71.43 ± 24.66 to 212.3 ± 54.96 at d14 p.t.; 
Fig. 2c,d). Increased T  cell cycling induced by CTLA-4 blockade 
alone, and more significantly in combination with PD-1 blockade, 
was coupled with a marked expansion of circulating effector-mem-
ory T  cells (TEM, CCR7−CD95+). With a full treatment cycle, the 
Fig. 1 | CTLA-4 and PD-1 blockade is biologically active in SIV-infected, ART-treated RMs. a, Study design. A total of 34 RMs were infected intravenously 
(i.v.) with 300 median tissue culture infectious dose (TCID50) SIVmac239. At d60 p.i. ART (FTC/DTG/TDF) was initiated and maintained for up to 13.5 
months. RMs were administered weekly i.v. ICB therapy over four weeks, and ART was interrupted two weeks afterwards with a seven-month follow-up. 
Peripheral blood (PB) and lymph node (LN) biopsies were collected at the specified time points. b,c,e,f, The frequency of residual PD-1 expression upon 
mAb occupancy relative to baseline (d–29 post-treatment (p.t.)) was longitudinally quantified at the masked EH12.2H7 locus in memory CD4+ and CD8+ 
T cells in PBMCs (b,c) and LNs (e,f). d,g, Representative stains are shown for PD-1 occupancy in memory CD4+ and CD8+ T cells (as indicated above; 
5 of 33 single-replicate stains within each parent per tissue) in PBMCs (d) and LN (g). h, Representative stains are shown for PD-1 occupancy against 
CXCR5 expression within LN memory CD4+ T cells over time by ICB treatment (indicated at the right; 6 of 99 single-replicate stains). i,j, The number and 
frequency of CD4+ TREGs cells (CD95+CD25+CD127−FoxP3+) were quantified in PB (i) and LN (j), respectively. RMs are color-coded and grouped based 
on ICB therapy as follows, with population sizes as indicated for all analyses: vehicle/dummy (VHDUM) mAbdAb (controls, n = 6), black; anti-CTLA-4 
mAb (αCTLA-4, n = 6), blue; anti-PD-1 mAb (αPD-1, n = 6), pink; anti-CTLA-4 plus anti-PD-1 mAb (combined blockade, n = 7), red; anti-CTLA-4/PD-1 
mAbdAb (BsAb, n = 8), purple. All averaged data are presented as mean ± s.e.m. and were analyzed (b,c,e,f,i,j) with a two-sided, mixed-effects model 
with Dunnett’s correction for multiple comparisons relative to controls. Color-coded statistical asterisks indicate significance between controls and the 
treatment group of the respective color. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
number of TEM increased from 111.9 ± 13.52 to 457.0 ± 66.30 cells 
per μl (P < 0.0001) for CD4+ T  cells and from 446.0 ± 165.5 
to 781.4 ± 196.9 cells per μl for CD8+ T cells (P = 0.0130; Fig. 2e,f) 
with combined blockade, while those levels remain virtually 
unchanged in controls or after αPD-1 monotherapy. Therefore, dual 
CTLA-4/PD-1 blockade exhibited strong synergy in enhancing the 
number of TEM and proliferative responses in PB.
In lymphoid tissue, CTLA-4 blockade enhanced Ki-67 expres-
sion in memory CD4+ T  cells (αCTLA-4, P = 0.0125; BsAb, 
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(Fig. 2h) and memory CD8+ T  cells (BsAb, P = 0.0235; com-
bined blockade, P = 0.0009; Fig. 2i). Dual blockade also uniquely 
increased activation (HLA-DR+CD38+) of both memory CD4+ 
(combined blockade, P = 0.0082; BsAb, P = 0.0200; Fig. 2j) and 
CD8+ T cells (combined blockade, P = 0.0221; Fig. 2k). Only dual 
blockade produced an increase in the frequency of CXCR3+ TFH 
cells, which produce interferon-γ (IFN-γ) and provide B cell help for 
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Fig. 2 | T cell proliferative and effector responses are synergistically improved by dual CTLA-4/PD-1 blockade. a–d, The number of cycling (Ki-67+) 
memory CD4+ (a) and CD8+ (c) T cells per μl of PB were measured, and representative longitudinal stains are shown within memory CD4+ (b) and CD8+ 
(d) T cells segmented by ICB (indicated at the right; RUm16 and 118_14 are shown as 12 of 198 single-replicate stains within each parental population). 
e–i, The number of CD4+ (e) and CD8+ (f) effector-memory cells (TEM; CD95+CCR7−) per μl of PB were quantified longitudinally as was the frequency 
of cycling cells in LN memory CD4+ (g), CD4+ TEM (h) and memory CD8+ (i) T cells. j–l, Following ICB (d28 p.t.), the frequency of immune activation 
(HLA-DR+CD38+) was quantified in LN memory CD4+ (j) and memory CD8+ (k) T cells, in addition to the frequency of CXCR3+ CD4+ TFH (CXCR5+PD-
1hiCD95+) (l). Individual animals are represented by open circles. All RMs are color-coded and grouped based on ICB therapy as follows, with population 
sizes as indicated for all analyses: controls (n = 6), black; αCTLA-4 (n = 6), blue; αPD-1 (n = 6), pink; combined blockade (n = 7), red; BsAb (n = 8), 
purple. All averaged data are presented as mean ± s.e.m. and were analyzed with a two-sided, mixed-effects model with Dunnett’s correction for multiple 
comparisons relative to controls (a,c,e,f–i) or a Mann–Whitney U test (j–l). Color-coded statistical asterisks indicate significance between control animals 
and the treatment group of that color. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 2l)21. Therefore, combined blockade results in increased T cell 
activation and cell cycling, suggesting the treatment may enhance 
viral reactivation and/or viral clearance.
SIV-specific CD8+ T cell responses are not improved by 
block-ade of PD-1 and/or CTLA-4 during long-term ART. 
Blockade of CTLA-4 and PD-1 signaling is predicted to 
improve the func-tion of exhausted cytotoxic T lymphocytes 
(CTL; that is ‘kill’). 
Immunophenotypic analysis revealed that dual blockade increased 
the frequency of granzyme B expression in LN CTLA-4+PD-1+ and 
CTLA-4+PD-1− subsets of memory CD8+ T  cells (Extended Data 
Fig. 4a,b). Following CellTrace labeling and T cell receptor stimula-
tion, combined blockade leads to a reduction of non-dividing CD4+ 
T cells at d21 p.t. (P = 0.0463), with a less pronounced effect within 
CD8+ T  cells (Supplementary Fig. 5a–d). Before therapy, SIV-
specific memory CD8+ T cells, as determined via Gag-CM9 tetra-
mer staining, were enriched in PD-1 and eomesodermin (EOMES), 
a T-box transcription factor that regulates T  cell exhaustion22,23 
(Extended Data Fig. 5a,b). ICB failed to substantially expand the 
frequency of SIV-specific memory CD8+ T cells in LN and PBMCs 
(Extended Data Fig. 6a,b) or to significantly enhance markers of 
activation, proliferation or cytolytic responses (Extended Data 
Fig. 5c–j). In ELISpot analyses in PBMCs and LN, none of the 
interventions increased IFN-γ production in response to SIV-
Gag (Extended Data Fig. 6c,d) or SIV-Env peptide stimulation 
(Supplementary Fig. 6a,b). Furthermore, αCTLA-4 monother-
apy resulted in a significant fold change reduction in SIV-Gag-
stimulated IFN-γ responses in PBMCs (P = 0.0411; Extended Data 
Fig. 6c) and a cross-sectional decrease in the SIV-Env-stimulated 
IFN-γ response in LN (Supplementary Fig. 6b). Finally, ICB failed 
to impact the frequency of PB memory T cells co-expressing inter-
leukin-2 (IL-2), IFN-γ, tumor necrosis factor-α (TNF-α) and/or 
CD107a following ex vivo SIV-Gag (Extended Data Fig. 6e,f) or 
SIV-Env peptide stimulation (Supplementary Fig. 6c,d). In SIV-Gag 
peptide responding T cells, defined as those expressing either IFN-γ, 
IL-2, TNF-α or CD107a, therapies incorporating CTLA-4 blockade 
significantly increased the frequency of proliferating memory CD4+ 
T cells relative to baseline (αCTLA-4, P = 0.0109; combined block-
ade, P = 0.0068) and combined blockade alone enhanced the pro-
liferation of memory CD8+ T cells relative to controls (P = 0.0259) 
(Supplementary Fig. 6e,f). Overall, these findings indicated that ICB 
is insufficient to enhance SIV-specific responses when performed in 
the context of long-term ART suppression.
CTLA-4 and PD-1 combined blockade induces robust viral 
reactivation in ART-treated, SIV-infected RMs. By promoting 
cell cycling, ICB is proposed to function as a latency-reversing 
agent (LRA) by increasing viral transcription24. Longitudinal 
quantification of plasma viral loads demonstrated detectable 
viral RNA on ART in a fraction of RMs across all interventions 
(Fig. 3a–e). Enhanced viral reactivation was observed for both 
co-blockades as compared to monotherapies, stratified either by 
animal or by the number of detectable events (Fig. 3f). In par-
ticular, combined blockade enhanced both the frequency (57.1% 
of RMs and 32.1% of events) and magnitude (average, 9.1 × 102 
SIV-RNA copies per ml) of detectable plasma SIV-RNA rela-
tive to controls (0% of events), αPD-1 (12.5% of events; 7.2 × 102  
SIV-RNA copies per ml) and αCTLA-4 monotherapy (12.5% of 
events; 7.1 × 102 SIV-RNA copies per ml), thus suggesting a syn-
ergistic effect of blocking PD-1 and CTLA-4 in reversing viral 
latency. Furthermore, measurable virus induction after ICB 
monotherapy skewed toward later treatments, with 66.7% of reac-
tivation events occurring after the third infusion, while both dual 
blockade strategies produced 66.7% of their reactivation events 
before the third infusion. As expected based on the early loss of 
PD-1 occupancy, the BsAb group produced fewer unique reactiva-
tion events following the third infusion as compared to combined 
blockade. The propensity towards viral reactivation was directly 
associated with the set-point plasma viral load (P = 0.0038; Fig. 3g 
and Extended Data Fig. 1), but not with peak viral load or the size 
of the SIV reservoir during suppressive ART (data not shown). 
Of note, only combined blockade yielded enhanced levels of cell-
associated SIV-RNA in PBMCs following the first (d7 p.t.) and 
fourth infusion (d28 p.t.) as compared to baseline (P = 0.0156; 
P = 0.0156; Fig. 3h). However, with some heterogeneity between 
individual animals, dual CTLA-4/PD-1 blockade acts as a syner-
gistic, latency-reversing intervention that induces robust levels of 
viral reactivation.
CTLA-4 and dual blockade, but not PD-1 blockade, reduces 
the total and intact SIV-DNA in LN. To determine the impact 
of ICB-induced viral reactivation and effector cell expansion on 
viral persistence, we longitudinally measured the levels of cell-
associated SIV-DNA with qPCR. In PBMCs, ICB did not impact 
viral DNA content relative to baseline (Extended Data Fig. 7a), 
but combined blockade increased the transcriptional ratio of 
SIV-RNA to SIV-DNA relative to baseline (P = 0.0313; P = 0.0156; 
Extended Data Fig. 7b), consistent with induction of viral expres-
sion. Mononuclear cells derived from LN, a major site of viral 
persistence25, were sorted for memory CD4+ T  cell subsets: TFH 
(PD-1+CD200hi), TREG (CD25+CD127−), central-memory (TCM, 
CCR7+) and effector-memory (TEM, CCR7−; Fig. 4a). Importantly, 
CTLA-4 blockade, whether as mono- or combination therapy, sig-
nificantly decreased cell-associated SIV-DNA in TEM (αCTLA-4, 
P = 0.0031; combined blockade, P = 0.0044; BsAb, P = 0.0147; 
Fig. 4b). The preferential reduction of SIV-DNA within the TEM 
compartment is consistent with the observation that this subset is 
the most affected in terms of cell cycling by combined blockade 
(Fig. 2h), perhaps suggesting the depletion of cycling cells in which 
SIV-RNA production was reactivated.
To assess if therapy-mediated reductions in total SIV-DNA 
translated into a functional decrease in intact virus, we assayed for 
integrated viral genomes in LN CD4+ cells using the intact proviral 
DNA assay (IPDA)26. The intact reservoir was remarkably stable in 
controls and with anti-PD-1 monotherapy (controls, 1,458 ± 475.4 to 
1,646 ± 424.5; αPD-1, 1,448 ± 300.6 to 1,514 ± 295.4 intact proviral 
Fig. 3 | CTLA-4 and PD-1 combined blockade induces robust viral reactivation in ART-treated, SIV-infected RMs. Single animal viral loads (SIVmac239 
RNA copies per ml of plasma) were quantified during ICB therapy on ART immediately before each infusion and one week following the terminal dose. 
a–e, Viral loads are segmented by treatment: control (n = 6) (a), αCTLA-4 (n = 6) (b), αPD-1 (n = 6) (c), combined blockade (n = 7) (d) and BsAb (n = 8) 
(e). The dotted horizontal line indicates the assay limit of detection (≤60 copies per ml), with undetectable events plotted as 30 copies per ml. The x 
axes are not drawn to scale—single time points have been spread and are grouped between dotted lines (as indicated below). f, Treatment-grouped 
reactivation events (>60 copies per ml) are displayed on a logarithmic scale. Progressive color shading indicates which infusion (number 1, 2, 3 or 4) the 
event followed (d7, 14, 21 or 28 p.t., respectively), and individual animals are indicated by shape. The frequency and number of reactivation events is given 
relative to the number of animals and the total number of assayed events per treatment (as indicated above). g, The set-point plasma viral load (d52 p.i.) 
was stratified by subsequent viral reactivation in plasma (positive, n = 13; negative, n = 14). h, The numbers of log-transformed cell-associated SIV-RNA 
copies per 106 cells in bulk PBMCs were quantified by 12 replicate quantitative polymerase chain reactions (qPCR) and segmented by treatment: control 
(n = 6), αCTLA-4 (n = 6), αPD-1 (n = 6), combined blockade (n = 7) and BsAb (n = 8). i, The number of viral lineages, as determined by sequencing of 
gp160 env, in plasma that reactivated on ART during ICB (left, ‘Reactivation’, n = 8) and during early rebound post-ATI (right, ‘Rebound’, n = 8) are shown. 
Viral lineages were deemed distinct if they differed by three or more nucleotide polymorphisms over gp160 env sequences. Individual RMs are indicated 
by shape with filled data points indicating viral reactivation in plasma. Averaged data are presented as mean ± s.e.m. and were analyzed using a two-sided 
Wilcoxon matched-pairs signed rank test (h) or Mann–Whitney U test (g).
genomes per 106 CD4+ cells, d–29 and d28 p.t., respectively). 
In comparison, all CTLA-4 blockades result in a fold change reduc-
tion in the frequency of intact provirus (Extended Data Fig. 7c,d), 
which was most pronounced, relative to baseline, for dual CTLA-4/
PD-1 blockade (combined blockade, P = 0.0860; BsAb, P = 0.0255, 
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To define the anatomic localization of SIV-RNA+ cells in LN, we 
employed RNAscope, an in  situ hybridization assay to detect and 
quantify cells harboring SIV-RNA (vRNA+) by tissue location27. 
Only combined blockade showed a significant reduction in the 
number of vRNA+ cells normalized per 105 cellular nuclei as com-
pared to baseline (P = 0.0312; Extended Data Fig. 8a), which was 
confirmed specifically within the BCF (P = 0.0312; Fig. 4d,e) and 
not within the TCZ or the medullary cords (not shown). The decline 
in BCF-resident vRNA+ cells in combination with heightened pro-
liferative capacity in LN memory CD4+ T  cells (Fig. 2g) suggests 
that combined blockade has the potential to target and reduce a sub-
set of cells undergoing viral reactivation. Finally, only BsAb-treated 
RMs showed a measurable decrease in vDNA+ cells, quantified by 
DNAscope and normalized per 105 cells, in the BCF (P = 0.0391; 
Fig. 4f) and TCZ (P = 0.0156, Fig. 4g; representative images are 
shown in Fig. 4h), and treatment did not differentially impact T cell 
or macrophage viral reservoirs (Extended Data Fig. 8b–d). As a 
caveat, DNAscope cannot distinguish between defective and intact 
viral genomes; however, we did observe a correlation between the 
reservoir content as determined by IPDA and DNAscope following 
therapy (Extended Data Fig. 8e). Collectively, these results highlight 
that, in lymphoid tissue, combined blockade limits SIV reservoir 
content within CD4+ TEM concomitant with reduced viral produc-
tion and persistence in the BCF, suggesting a direct link between 
viral reactivation and clearance in a fraction of infected cells.
Dual CTLA-4/PD-1 blockade does not control or delay viral 
rebound after ATI. To functionally assess the impact of ICB on 
the size of the viral reservoir we conducted an ATI two weeks after 
ICB cessation. Overall, there was a limited impact on delaying viral 
rebound, with αPD-1 treatment (P = 0.0390) and dual CTLA-4/
PD-1 blockade producing a slight delay in time to measurable 
viral rebound as compared to controls (control, 7.67 ± 0.82 days; 
αCTLA-4, 8.00 ± 0.52 days; αPD-1, 12.83 ± 2.04 days; combined 
blockade 10.29 ± 1.69 days; BsAb, 12.75 ± 3.48 days; Extended Data 
Fig. 9a–f). Twelve of 13 RMs with prior ICB-mediated viral reac-
tivation re-established undetectable plasma viremia between their 
terminal on-ART reactivation event and the first post-ATI obser-
vation, consistent with the observed on-ART viremia being LRA-
mediated and not a failure of the ART regimen. All blockades failed 
to significantly attenuate the set-point plasma viral load post-ATI 
(Extended Data Fig. 9g), the fold change in peak viremia relative to 
acute infection (not shown) and the fold change in set-point viremia 
at necropsy (d170 post-ATI) relative to chronic infection (d52 p.i.; 
Extended Data Fig. 9h) as compared to controls. Furthermore, ICB 
failed to impact on cell-associated SIV-DNA or SIV-RNA levels, or 
their respective ratio in axillary LN or spleen at necropsy (Extended 
Data Fig. 9i and Supplementary Fig. 7). Of note, post-ATI viremia 
was associated with a robust induction of proliferation, activation 
and CTL functionality in SIV-specific memory CD8+ T cells rela-
tive to during ART, suggesting a critical dependence on sufficient 
antigen burdens (Extended Data Fig. 5g–j). Thus, the potent latency 
reversal and the partial reduction of the viral reservoir induced by 
combined CTLA-4 and PD-1 blockade under long-term ART is 
insufficient, alone, to control viral rebound after ART interruption.
Finally, single-genome sequencing of gp160 env was performed 
on plasma during on-ART, ICB-mediated viral reactivation (n = 8) 
and at rebound following ATI (n = 8). Qualitatively, all RMs across 
ICB treatments yielded a similar number of viral lineages dur-
ing rebound (3–10 lineages; Fig. 3i), consistent with a polyclonal 
nature of the seeded, latent viral reservoir and rebound virus28. Only 
αPD-1 monotherapy was associated with highly restricted clonality 
in reactivating virus (that is, a single lineage), whereas virus aris-
ing from αCTLA-4 monotherapy (2–7 lineages) and dual blockade 
(combined blockade, 5–7 lineages; BsAb, 4–7 lineages) was poly-
clonal in nature (Fig. 3i and Extended Data Fig. 10). These data sug-
gest that combination CTLA-4/PD-1 blockade was able to reactivate 
a larger and more diverse latent reservoir as compared to αPD-1 
monotherapy (Supplementary Table 3).
Discussion
The quest for a functional cure for HIV is hampered by a limited 
understanding of the mechanisms underlying the long-term persis-
tence of HIV reservoirs, including both latently and actively infected 
cells, the absence of reliable biomarkers for the selective targeting of 
latently infected cells, the lack of potent LRAs that induce robust 
viral reactivation during suppressive ART and the inhibition of 
HIV-specific cytotoxic T cell responses mediated by co-inhibitory 
signaling arising from chronic immune activation. The results of 
the current study indicate that CTLA-4 blockade, particularly when 
combined with PD-1 blockade, enhances activation, proliferation 
and expansion of LN and PB memory CD4+ and CD8+ T  cells, 
including TEM cells. In contrast, anti-PD-1 monotherapy showed 
limited effects on reversing the negative regulation of T cell activa-
tion. Of note, combined blockade potently enhanced viral reacti-
vation on ART, as measured by plasma viremia, among the most 
persistent published so far, and increased the levels of cell-associ-
ated SIV-RNA in PBMCs. Furthermore, RMs receiving combined 
CTLA-4/PD-1 blockade showed a greater number of reactivated 
viral lineages compared to anti-PD-1 monotherapy. These findings 
suggest that blocking CTLA-4 co-inhibitory signaling, especially in 
combination with PD-1 blockade, is critical to reverse latency in a 
larger subset of memory CD4+ T cells during long-term ART.
Although combined blockade-induced proliferation provided an 
effective ‘shock’ to break viral latency in memory CD4+ T cells, this 
treatment, as well as the αCTLA-4 and αPD-1 monotherapies, failed 
to induce a significant functional reversal of exhaustion. Previous 
in  vivo PD-1 blockades in SIV-infected RMs have demonstrated 
Fig. 4 | CTLA-4 and dual blockade, but not PD-1 blockade, reduces the total and intact SIV-DNA in LN. a,b, In LN, memory subsets in CD4+ T cells 
were sorted at d28 p.t., shown in a representative gating strategy (1 of 33 single-replicate runs; RTj16) (a), and the cell-associated SIV-DNA content was 
determined via 12 replicate reaction qPCR with reverse transcription (RT-qPCR) (b). Within the memory CD4+ T cells, the sorted populations are defined 
as follows: TFH, PD-1hiCD200hi; TREG, PD-1loCD200loCD127−CD25+; TCM, PD-1loCD200loCD25−CCR7+; TEM, PD-1loCD200loCD25−CCR7−. c, With eight replicate 
reaction intact proviral DNA assays (IPDAs), the numbers of intact proviral genomes per 106 CD4+ cells were quantified in LN at pre-treatment baseline 
(d–29 p.t.) and following the fourth ICB (d28 p.t.): control (n = 3), αCTLA-4 (n = 6), αPD-1 (n = 6), combined blockade (n = 7) and BsAb (n = 7). d,e, By 
using RNAscope, the numbers of vRNA+ cells per 105 cells were measured in the lymphoid B cell follicle (BCF) (d) and a representative stain is shown 
for vRNA (red) in the LN BCF both pre- and post-treatment (combined blockade-treated RVr16; 1 of 33 unique samples quantified from up to two tissue 
sections) (e). The distance scale is given below each panel with successive magnifications within the indicated area (black square) extending to the right. 
f,g, Using DNAscope, the numbers of vDNA+ cells per 105 cells were quantified in the lymphoid BCF (f) and the T cell zone (TCZ) (g). h, A representative 
stain (BsAb-treated RKt16; 1 of 33 unique samples quantified from up to two tissue sections) is shown for vDNA (red). For all analyses, except IPDA as 
indicated, annotations and population sizes are as follows: controls (n = 6), black; αCTLA-4 (n = 6), blue; αPD-1 (n = 6), pink; combined blockade (n = 7), 
red; BsAb (n = 8), purple. Individual RMs are indicated by shape, with filled data points indicating viral reactivation in plasma. Averaged data are presented 
as mean ± s.e.m. and were analyzed with a two-sided two-way analysis of variance (ANOVA) or a mixed-effect model with Dunnett’s correction relative to 
controls (b), Bonferroni’s corrections for multiple comparisons relative to baseline (c) or a Wilcoxon matched-pairs signed rank test (d,f,g).
marked enhancement of SIV-specific antiviral responses; however, 
they were conducted in the absence of ART16,29,30 and either before 
ART initiation or during short-term ART with detectable viral 
loads17,29,31, suggesting that the presence of antigen at the time of 
PD-1 blockade is important for breaking the exhausted phenotype. 
Consistently, PD-1 blockade failed to improve antiviral immune 
responses when performed in SIV-infected RMs after more than 
two years of ART18. PD-1 blockade was also shown to restore CTL 
responses in HIV-infected, ART-treated humans in vivo in the con-
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indicates that ICB, even when targeting both PD-1 and CTLA-4, 
is unlikely to induce HIV remission if performed in the context of 
sustained aviremia and in the absence of additional interventions.
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impact on the HIV reservoir and CTL function has been highly 
variable12. If ICB efficacy is dependent on a critical antigen concen-
tration, restoration of HIV-specific responses may require extensive 
pretreatment with additional LRAs, as concurrent virus reactivation 
during ICB was not associated with CTL enhancement.
Dual CTLA-4/PD-1 blockade produced a significant reduc-
tion in cell-associated SIV-DNA within LN CD4+ TEM, the CD4+ 
T  cell subpopulation most activated from combined treatment. 
Importantly, in situ hybridization assays demonstrated a significant 
reduction in the number of vRNA+ and vDNA+ cells following dual 
CTLA-4/PD-1 blockade in the LN, including in the BCF. Finally, 
dual CTLA-4/PD-1 reduced the frequency of LN CD4+ cells har-
boring intact proviral DNA as determined by IPDA. Of note, PD-1 
blockade alone did not impact any measure of viral persistence. We 
have previously shown that in ART-treated RMs a large fraction of 
LN CD4+PD-1+ T cells that reside within the BCF that are preferen-
tially enriched for vDNA also express CTLA-41. Given their expres-
sion of both ICRs, these cells probably represent a preferentially 
responsive target to dual blockade. Together, these findings suggest 
a link between viral reactivation and clearance, at least in a subset 
of infected cells.
Following ART withdrawal, combined blockade did not impact 
the delay in viral rebound or the set-point viral load. In this regard, 
in the current study ART was initiated at d60 p.i., substantially later 
than in other NHP studies involving ATI, and therefore with a larger 
and more disseminated reservoir and development of T cell exhaus-
tion32,33. The inability of the combined blockade to extend the αPD-1 
monotherapy-mediated five-day delay in viral rebound suggests 
that αCTLA-4-driven TREG responses and/or some level of reser-
voir reseeding caused by viral reactivation may have been sufficient 
to abrogate the antiviral synergy between the two treatments34,35. 
Unexpectedly, dual CTLA-4/PD-1 blockade was well tolerated in 
NHP, whereas similar regimens were found to be associated with a 
substantial risk of serious immune-related adverse events in human 
clinical trials for cancer36–39. At present, it is unknown whether 
CTLA-4 or dual CTLA-4/PD-1 blockade would exhibit acceptable 
toxicity profiles in ART-treated people living with HIV without co-
morbidities. It is plausible that the onset of toxicity could be linked 
with factors such as the timing of intervention (that is, the presence 
and burden of antigen), the duration or interval of therapy, or the 
extent of T cell exhaustion (that is, the frequency and distribution of 
ICR expression). Our study highlights the need to better understand 
how tolerability changes in different preclinical and clinical settings 
while balancing the need for immunological efficacy with accept-
able profiles of toxicity.
This study represents the first in  vivo combined ICB in 
SIV-infected, ART-treated RMs with a high barrier for cure, 
designed to mimic issues pertaining to treatment in people living 
with HIV, albeit with a shorter duration of ART than would be 
expected in humans. We have demonstrated that CTLA-4 
blockade in SIV-infected, ART-treated RMs produces robust 
T cell proliferation and TEM expansion that synergizes with PD-1 
blockade to enhance viral reactivation in PBMCs and plasma, 
decrease the SIV-DNA content in LN TEM, reduce the number of 
vDNA+ and RNA+ cells in the LN BCF and limit the levels of 
intact provirus in LN. Thus, combined ICB induces latency 
reversal and a partial reduction of the reacti-vated reservoir, two 
critical steps towards eradication of the per-sistent reservoir of 
latently HIV-infected cells. Our data highlight the possibility 
that re-invigoration of antiviral responses through relieving 
T cell exhaustion may be dependent on antigen burden. As 
such, ICB might be more beneficial in antigen-rich phases of 
HIV infection (such as during ATI or at the time of ART 
initiation), in subjects that started ART in acute infection (to 
limit the extent of T cell exhaustion and viral reservoir seeding) 
or in combination with enhanced killing strategies, such as 
therapeutic vaccinations40 or co-administration of neutralizing 
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anti-CD25-BV711 (clone BC96, cat no. 302636), anti-CD20-PerCp/Cy5.5 (clone 
2H7, cat no. 302326) and anti-PD-1-BV785 (clone EH12.2H7, cat. no. 329930) (all 
from Biolegend); anti-CXCR5-PE (clone MU5UBEE, cat. no. 12-9185-42) and anti-
CD127−PE-Cy5 (clone eBioRDR5, cat. no. 15−1278-42) (eBioscience); anti-CCR7-
PE-Cy7 (clone 3D12, cat. no. 557648), anti-Ki-67-Alexa700 (clone B56, cat. no. 
561277), anti-CTLA-4-BV421 (clone BNI3, cat. no. 562743), anti-CD3-BUV395 
(clone SP34-2, cat. no. 564117), anti-CD8-BUV496 (clone RPA-T8, cat. no. 564804) 
and anti-CD28-BUV737 (clone CD28.2, cat. no. 564438) (BD Biosciences); anti-
LAG-3-FITC (clone 17B4, cat. no. NBP1-97665) (Novus Biologicals); Aqua Live/
Dead amine dye-AmCyan from Invitrogen (cat. no. L34966). The following 
antibodies were used for phenotyping cryo-preserved LN: anti-CD200-PE (clone 
OX104, cat. no. 329206), anti-HLA-DR-PE-Cy5 (clone L243, cat. no. 307608), anti-
CD4-APC-Cy7 (clone OKT4, cat. no. 317418), anti-CD25-BV711 (clone BC96, cat. 
no. 302636), anti-CD101-PerCP/Cy5.5 (clone BB27, cat. no. 331016), anti-CD95-
BV605 (clone DX2, cat. no. 305628) and anti-CD69-BV785 (clone FN50, cat. no. 
310932) (Biolegend); anti-CD38-FITC (clone AT-1, cat. no. 10415) (STEMCELL 
Technologies); anti-CCR7-PE-Cy7 (clone 3D12, cat. no. 557648), anti-Ki-67-
Alexa700 (clone B56, cat. no. 561277), anti-CTLA-4-BV421 (clone BNI3, cat. no. 
562743), anti-CXCR3-BV650 (clone 1C6/CXCR3), anti-CD3-BUV395 (clone 
SP34-2, cat. no. 564117), anti-CD8-BUV496 (clone RPA-T8, cat. no. 564804) and 
anti-CD28-BUV737 (clone CD28.2, cat. no. 564438) (BD Biosciences); anti-PD-
1-Alexa647 (clone 913429, cat. no. MAB10861; 1:50 dilution) (Novus Biologicals); 
anti-Granzyme B-PE-Texas Red (clone GB11, cat. no. GRB17) and Aqua Live/
Dead amine dye-AmCyan (cat. no. L34966) (Invitrogen). The following panel 
of antibodies was utilized for measuring cytolytic and SIV-specific responses in 
cryo-preserved cells: anti-CD3-BUV395 (clone SP34-2, cat. no. 564117), anti-
CD8-BUV496 (clone RPA-T8, cat. no. 564804), anti-Ki-67-AL700 (clone B56, 
cat. no. 561277), anti-CD95-PE-Cy5 (clone DX2, cat. no. 559773), anti-CCR7-
BV480 (clone 3D12, cat. no. 566099), anti-Granzyme B-BV421 (clone GB11, 
cat. no. 563389) and anti-CD28-BUV737 (clone CD28.2, cat. no. 612815) (BD 
Biosciences); anti-HLA-DR-BV750 (clone L243, cat. no. 307672), anti-CD4-
BV570 (clone OKT4, cat. no. 317445), anti-PD-1-BV786 (clone EH12.2H7, cat. 
no. 329930) and anti-CTLA-4-PE (clone BNI3, cat. no. 369604) (Biolegend); 
anti-Gag-APC (clone CM9, 4.2 µg per test) from the NIH Tetramer Facility at 
Emory University45; anti-CD38-APC (clone AT-1, cat. no. 60131FI) (STEMCELL 
Technologies); anti-EOMES-PE-eFluor610 (clone WD1928, cat. no. 611-4877-42) 
and LIVE/DEAD Fixable Near-IR Dead Cell Stain (cat. no. L34976) (Thermo 
Fisher Scientific). All mAbs were used at the manufacturer’s recommended test 
volume per 106 mononuclear cells (1:100 dilution) unless otherwise noted.
Purified anti-PD-1 (clone 913429, cat. no. MAB10861; Novus Biologicals) was 
labeled using an Alexa Fluor 647 Antibody Labeling Kit (Invitrogen) using the 
manufacturer’s guidelines. To detect intracellular expression of FoxP3, mononuclear 
cells were fixed and permeabilized with FoxP3/Transcription Factor Staining 
Buffer Kit Fix/Perm (Tonbo), and subsequently stained intracellularly; otherwise 
a BD Cytofix/Cytoperm kit (BD Biosciences) was employed. To determine the ex 
vivo expression of CTLA-4+ in CD4+ and CD8+ T cells, staining was performed 
intracellularly in unstimulated T cells1. Flow cytometry acquisition was performed 
on a minimum of 120,000 live CD3+ T cells for LN and PBMCs. Data acquisition 
was performed on an LSRFortessa or FACSymphony (BD Biosciences) driven by 
FACS DiVa software and analyzed using FlowJo software (version 9.9.6, TreeStar).
Flow cytometry cell sorting. Cryo-preserved, unstimulated mononuclear cells 
derived from LN biopsies were stained with the following combination of RM-
reactive, anti-human mAbs (NHP Reagent Resource)1,44: anti-CD200-PE (clone 
OX104, cat. no. 329206), anti-CD25-Alexa700 (clone BC96, cat. no. 302622)  
and anti-CD4-BV650 (clone OKT4, cat. no. 317436) (Biolegend); anti-CD28-PE-
CF594 (clone CD28.2, cat. no. 562296), anti-CCR7-PE-Cy7 (clone 3D12, cat. no. 
557648), anti-CD3-APC-Cy7 (clone SP34-2, cat. no. 557757) and anti-CD95-
BV421 (clone DX2, cat. no. 562648) (BD Biosciences); anti-CD8-FITC (clone 3B5, 
cat. no. MHCD0801) and Aqua Live/Dead amine dye-AmCyan (cat. no.  
L34966) (Invitrogen); anti-CD127-PE-Cy5 (clone eBioRDR5, cat. no. 15-1278-
42) (eBioscience); anti-PD-1-Alexa647 (clone 913429, cat. no. MAB10861; 
1:50 dilution) (Novus Biologicals). All mAbs were used at the manufacturer’s 
recommended test volume (1:100 dilution) scaled per 107 mononuclear cells 
unless otherwise noted. Purified anti-PD-1 was labeled using an Alexa Fluor 
647 Antibody Labeling Kit (Invitrogen) using the manufacturer’s guidelines. The 
following memory subsets of CD4+ T cells were sorted on a fluorescence-activated 
cell sorting (FACS) Aria II system (BD Biosciences): TFH, TREG, TEM and TCM. For 
phenotypic discrimination, TFH were defined as PD-1hiCD200hi, whereas TREG
(CD25+CD127−) were pre-gated as PD-1loCD200lo to avoid inclusion of CD25+ 
TFH cells and T follicular regulator (TFREG) cells46. Within the CD25−PD-1loCD200lo 
population, TEM and TCM were sorted based on their CCR7 expression. Sorted 
CD4+ T cell subsets were on average >96% pure as determined by post-sorting 
flow cytometry analysis. See Fig. 4a for a representative gating strategy.
Determination of viral load RNA. The number of SIVmac239 RNA copies per ml 
of plasma was quantified, as previously described, by RT-qPCR47 or by PCR48 with 
a limit of detection of 15 copies per ml and 60 copies per ml, respectively; therefore, 
the higher limit of detection was utilized for all datasets.
Methods
Animals, SIV infection and ART. Thirty-four male Indian RMs (Macaca mulatta), 
all housed at the Yerkes National Primate Research Center (YNPRC), were 
included in this study. All RMs were Mamu-B*07− and Mamu-B*17−, with the 
following being Mamu-A01+: RGi16, RKt16, RVr16, RHn16, RPo16 and RZw15. 
RMs were screened for pathogens and housed as previously described1.
All RMs were infected i.v. with 300 TCID50 SIVmac239 (Fig. 1a). At 60 days 
p.i., all RMs initiated a daily ART regimen consisting of DTG (2.5 mg kg−1 d−1, 
subcutaneous (s.c.)), TDF (5.1 mg kg−1 d−1, s.c.) and FTC (40 mg kg−1 d−1, s.c.)41, 
maintained for up to 13.5 months (Extended Data Figs. 1 and 2a). RMs were 
then stratified into treatment groups based on their projected time of virologic 
suppression under ART, Mamu-A*01 status and presence of ADAs during chronic 
infection (d52 p.i.; Supplementary Fig. 1 and Supplementary Table 1). After a 
minimum of three discontinuous months of undetectable plasma viral loads 
(181.4 ± 4.9 days; limit of detection ≤60 copies per ml) animals were administered 
ICB mAbs once per week over four weeks. After a two-week washout period, 
RMs underwent an ART ATI and were followed for up to seven months with a 
subsequent necropsy. RFf16 was euthanized at d25 p.i. due to rapid progression to 
AIDS-defining endpoints, specifically attributable to weight loss.
Study approval. All animal experimentation was conducted under anesthesia with 
follow-up pain management following guidelines set forth by the Animal Welfare 
Act and by the NIH’s Guide for the Care and Use of Laboratory Animals (8th 
edition). All studies were conducted in accordance with institutional regulations 
including GSK’s Policy on the Care, Welfare and Treatment of Laboratory 
Animals, and were reviewed and approved by Emory’s Institutional Animal 
Care and Use Committee (IACUC; permit nos. 3000065, 2003297, 2003470 and 
PROTO201700665). Animal care facilities at YNPRC are accredited by the US 
Department of Agriculture (USDA) and the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) International.
Immune checkpoint blockade. ICR blocking mAbs were developed, formulated 
and produced by GlaxoSmithKline and provided via Qura Therapeutics. The 
described therapeutics are the intellectual property of GlaxoSmithKline and 
are not commercially available. VHDUM, the control, is a fully human IgG1 
mAbdAb with the Fc region disabled by the LAGA mutations L235A and G237A. 
The mAb portion has the sequence of palivizumab (anti-respiratory syncytial 
virus, MedImmune) and is linked by a fibronectin linker to an irrelevant domain 
antibody that has no known specificity. The IgG4 anti-PD-1 mAb (αPD-1) is a 
biosimilar formulation of nivolumab (Bristol-Myers Squibb) with a human variable 
region and a rhesus constant region. The IgG1 anti-CTLA-4 mAb (αCTLA-4) 
is a fully human, biosimilar formulation of ipilimumab (Bristol-Myers Squibb) 
that retains Fcγ binding activity. The IgG1 bispecific αCTLA-4/PD-1 mAbdAb 
(BsAb) has a human variable and rhesus constant region with a LAGA mutation-
disabled Fc receptor, and was constructed with a flexible fibronectin linker 
connecting the C terminus of the mAb heavy chain to a PD-1 domain antibody 
(dAb)42. The antagonistic anti-PD-1 dAb was identified through phage display, 
and bound PD-1-expressing cells with a half-maximum effective concentration 
of 2 nm, thereby efficiently blocking interactions with PDL-1/PDL-243. The BsAb 
CTLA-4 is biosimilar to ipilimumab and the PD-1 is a proprietary formulation of 
GlaxoSmithKline (Extended Data Fig. 2b). Optimal dosing concentrations and 
intervals were determined in a pharmacokinetics and pharmacodynamics pilot 
study in drug-naïve, uninfected RMs conducted by Convance Research Products 
on behalf of GlaxoSmithKline (data not shown).
Pre-filtered, endotoxin-free compounds were provided in sterile, glass dosing 
vials that were stored long-term at −80 °C. Agents were administered under 
anesthetic sedation as an i.v. bolus push over ~15 min without pretreatment 
prophylaxis. Doses administered were as follows: control, 30 mg kg−1 (n = 6); 
αCTLA-4, 5 mg kg−1 (n = 6); αPD-1, 5 mg kg−1 (n = 6); αCTLA-4 plus αPD-1 
(combined blockade), 5 mg kg−1 each (n = 7); BsAb, 5 mg kg−1 (n = 8). 
Diphenhydramine (1–2 mg kg−1, i.v.) and dexamethasone (0.3 mg kg−1, i.v.) 
were available in the event of a suspected adverse event, such as anaphylaxis or 
respiratory distress. Endpoint criteria included the onset of adverse events that 
required steroids to control.
Sample collection and processing. Collections of PB and LN biopsies were 
conducted longitudinally and at necropsy (Fig. 1a) as previously described1 with 
the following exception: during ICB infusions, blood was drawn prior to and 5 min 
afterwards for pharmacokinetic assays.
Flow cytometric analysis. An 18-parameter flow cytometric analysis was 
performed on PBMCs and mononuclear cells derived from LN biopsies. Samples 
were stained utilizing standard procedures with anti-human mAbs that we, and 
others, have shown to be cross-reactive in RMs1,44, and those clones verified as 
RM reactive (NHP Reagent Resource). The following antibodies were used at 
predetermined optimal concentrations for the longitudinal staining panel: anti-T-
bet-PE/Dazzle-594 (clone 4B10, cat no. 644828), anti-FoxP3-APC (clone 150D, cat 
no. 320014), anti-CD4-APC-Cy7 (clone OKT4, cat no. 317418), anti-CD95-BV605 
(clone DX2, cat no. 305628), anti-HLA-DR-BV650 (clone L243, cat no. 307650), 
Quantitation of cell-associated SIV-DNA and SIV-RNA. Analyses were performed 
on FACS-sorted memory CD4+ T cell subsets from LN biopsies and on bulk snap-
frozen PBMCs. SIV-DNA and SIV-RNA were extracted using an AllPrep DNA/
RNA Mini Kit (Qiagen). SIV-DNA and SIV-RNA in tissue was assessed using hybrid 
real-time/digital PCR and RT-qPCR assays in 12 replicate reactions with single-copy 
clinical sensitivity, as previously described49. Viral copy numbers were reported 
normalized based on CCR5 DNA copy numbers. Assays for which there were fewer 
than 10 positive amplifications per replicates were calculated using Poisson methods.
Chromogenic SIV-RNA and SIV-DNA in situ hybridization and image analysis. 
RNAscope was performed on formaldehyde-fixed, paraffin-embedded (FFPE) 
tissue sections (5 mm) according to our previously published protocol27 with the 
following minor modifications: heat-induced epitope retrieval was performed 
by boiling slides in 1× target retrieval (322000, ACD) for 30 min, followed by 
incubation at 40 °C with a 1:10 dilution of protease III (322337, ACD) in 1× 
phosphate buffered saline (PBS) for 20 min. Slides were incubated with the target 
probe SIVmac239 (312811, ACD) for 2 h at 40 °C. Amplification was performed with 
RNAscope 2.5 HD Detection kits (322360, ACD) according to the manufacturer’s 
instructions with 0.5× wash buffer (310091, ACD) used between steps. The 
resulting signal was detected with Warp Red chromogen (WR806M, Biocare 
Medical). Slides were counterstained with CAT hematoxylin (CATHE-GL, Biocare 
Medical), mounted with Clearmount (17885-15, EMS) until dry, cover slipped 
using Permount (SP15-100, Fisher Scientific) and scanned at ×40 magnification 
on an Aperio AT2 system (Leica Biosystems). DNAscope was performed on 
FFPE tissue sections as above except that a 1:5 dilution of protease III and an in-
house 3% H2O2 in PBS solution were used, slides were incubated with the target 
probe SIVmac239 sense (314071, ACD) for 4 h at 40 °C, and the wash steps after 
amplification steps 5 and 6 were performed using 1× Tris-buffered saline with 
0.05% Tween 20 (TBS-T).
Quantitative image analysis of RNAscope whole-tissue images was performed 
to determine the total number of SIV vRNA+ cells per 105 total cells using the 
CytoNuclear module (v1.6) within Halo software (v2.3.2089.27, Indica Labs). 
Specific regions of the LN (B cell follicle, T cell zone and medullary cord) were 
manually highlighted in Halo based on CD4/CD20 staining of subjacent slides. 
Using the Stain 1Min OD slider in the CytoNuclear module on concomitantly 
assayed, early chronic infection SIV+ control slides, we set the vRNA minimum 
signal size to exclude detection of the smaller single vRNA and/or vDNA 
molecules. DNAscope images were analyzed for the total number of vDNA+ cells 
per 105 total cells using the ISH module (v3.0.2; for quantifying the number of 
vDNA+ cells) and the CytoNuclear module (v1.6; for quantifying the number of 
total cells) within Halo. We set the vDNA minimum and maximum signal spot 
sizes by adjusting the Probe 1 spot size setting in the ISH 3.0.2 module on SIV+ 
control slides to capture only cells with one, and occasionally more than one, 
clear punctate dots within their nuclei. In all quantifications, manual curation 
was performed on each sample to correct for false positives and false negatives. 
Analyses were performed blinded for ICB therapy.
Fluorescence multiplex SIV-RNA and SIV-DNA in situ hybridization with CD3 
and myeloid cell staining and image analysis. DNAscope and RNAscope were 
performed sequentially as described above, with the following modifications: for 
DNAscope, slides were kept wet following paraffin removal and antigen retrieval 
prior to the addition of the SIVmac239 sense (314071, ACD) probe for 14 h at 40 °C. 
Amplification was performed with the RNAscope 2.5 HD Detection kit–Brown 
(322310, ACD) and the signal was developed with tyramide-conjugated Alexa 
Fluor 647 (B40958, Invitrogen). Slides were placed for 10 min in 1× target retrieval 
(322000, ACD) at 95 °C, cooled and probed for 2 h with SIVmac239 (312811, 
ACD). Following amplification as above, the signal was developed with tyramide-
conjugated Alexa Fluor 568 (B40956, Invitrogen). Slides were then incubated 
overnight with antibodies against the myeloid markers CD68 (CM033C, Biocare) 
and CD163 (MA5-11458, Invitrogen) at 1:400 each, and the T cell marker CD3 
(RM-9107-S, Thermo Scientific) at 1:200, and detected with donkey anti-mouse 
Alexa Fluor 488 (A21202, Invitrogen) and donkey anti-rabbit DyeLight 755  
(SA5-10043, Invitrogen) at 1:500 for 1 h, respectively.
To quantify the number of SIV vDNA+ lymphocytes or myeloid cells on 
stained tissues, whole-slide high-resolution fluorescent scans were performed at 
×20 using the Zeiss Axioscan Z.1 slide scanner. DAPI, Alexa Fluor 488, Cy5 (for 
Alexa Fluor 647) and Cy7 (for Alexa Fluor 750) channels were used to acquire 
images. The exposure time for image acquisition was between 4 and 150 ms. 
Multi-spectral images were analyzed using the HALO 2.3 platform (Indica Labs) 
using the following analysis methods: for SIV vDNA, cells with clear punctate dots 
were quantified using the module FISH v1.1. using a similar thresholding method 
as in the analysis of the chromogenic staining. Putative positive signals were 
further selected by fine filtering based on signal area and average intensity. For 
quantification of SIV vRNA+ cells, the same FISH v1.1 module was also used with a 
minimum signal size set to exclude cells with single vRNA/vDNA signals. Manual 
curation was performed on each sample to correct for false positives and negatives. 
High-resolution representative images were taken using the Keyence BZ-X710 
fluorescence microscope with the ×20 objective using the Z-stack and Full Focus 
functions. The exposure time for image acquisition was between 2 ms and 10 s.
Quantification of anti-drug antibodies in plasma. Plasma samples collected 
before and after antibody infusion were thawed, mixed with assay diluent (casein 
in PBS, Thermo Fisher Scientific), and added to the assay plate along with 
two concentrations (low and high) of the positive control (JDC-10, Southern 
Biotech) and a negative control (pool of normal RM plasma). Each antibody 
was biotinylated and sulfo-tagged with a 1:1 mixture of biotin-Ab and sulpho-
tag-Ab at 1 µg ml−1 in casein and added to the assay plate. The assay plate was 
sealed and placed on a shaker for more than 2 h at room temperature to allow 
complex formation. During the incubation, blocking buffer (Smartblock, Candor 
Biosciences) was added to a Meso Scale Discovery (MSD) standard streptavidin 
plate for 2 h at room temperature with shaking. Blocking solution was removed 
from the MSD-SA plate and a 50 µl volume of sample from the assay plate was 
added in duplicate to MSD-SA blocked plates. Plates were sealed, incubated 
in the dark for 1 h with continuous shaking, washed three times with 300 µl 
PBS with 0.1% Tween 20, and MSD read buffer was added. Plates were read 
on an MSD Imager and the levels of anti-drug antibodies were quantified by 
electrochemiluminescence (ECL).
Determination of pharmacokinetics of monoclonal antibodies in plasma.  
The respective antigen (CTLA-4 or PD-1 protein) was diluted into PBS and coated 
onto each well of a microtiter plate for at least 12 h at 4 °C. Plates were washed 
five times with 25 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.5 (wash buffer). 
A 150 µl volume of blocking assay buffer (Superblock TBS-T20, Thermo Fisher 
Scientific) was added and the plates were sealed and incubated for at least 1 h 
with constant shaking. Plasma samples collected pre- and 5 min post-infusion 
were serially diluted 50-fold into assay buffer. Samples needing further dilution 
were diluted into assay buffer containing 2% cynomolgus macaque serum. After 
washing, sample was added to each well of the microtiter plate as appropriate: test 
sample, blank, calibration standard or quality controls (that is, antibody diluted 
into plasma from healthy RMs, Bioreclamation). Plates were sealed and incubated 
with constant shaking for 2 h at 37 °C. Plates were then washed, detection solution 
was added (ruthenium-labelled mouse anti-human IgG Fc JDC-10 from Southern 
Biotech or ruthenium-labelled PD-1 from GSK), and plates were incubated with 
constant shaking for 1 h at 37 °C. Plates were once again washed, read buffer T 
(Meso Scale Discovery) was added to each well, and plates were read within 5 min 
on an MSD Sector S600 instrument.
ELISpot for the quantification of IFN-γ response upon SIV-Gag and SIV-Env 
stimulation. Cryo-preserved PBMCs and LN-derived mononuclear cells were 
thawed, rested and triplicate-plated at 4 × 105 cells per well. Cells were either 
unstimulated (DMSO) or stimulated with SIVmac239 overlapping Gag/Env peptides 
(NIH AIDS Reagent Program) at a concentration of 1 μg ml−1, or with concavalin 
A (Sigma) at 2.5 μg ml−1. Plates were incubated for 24 h at 37 °C and the number 
of cells secreting IFN-γ were evaluated using the Monkey IFN-γ ELISpotPLUS kit 
(MABTECH) acording to the manufacturer’s instructions. The number of spot-
forming units (SFUs) per well was enumerated on an ELISpot plate reader and 
expressed as SFUs per million cells. The IFN-γ response is shown as an average of 
triplicate reactions with the DMSO background subtracted out.
Determination of intracellular cytokine induction following SIV-Gag and 
SIV-Env peptide stimulation. Cryo-preserved PBMCs were thawed, rested and 
resuspended in RPMI 1640 (Invitrogen) supplemented with 10% FBS (Seradigm) 
in the presence of Golgi transport inhibitors, anti-CD107a-APC (clone H4A3, 
cat. no. 328620) from Biolegend, anti-CD49D (clone 9F10, cat. no. 304302) from 
BD Biosciences and anti-CD28-PE-Cy7 (clone CD28.2, cat. no. 25-0289-42) from 
eBiociences. PBMCs were either left unstimulated (DMSO) or stimulated for 6 h 
at 37 °C with either SIVmac239 overlapping Gag/Env peptides (NIH AIDS Reagent 
Program) at a concentration of 1 μg ml−1 or staphylococcal enterotoxin A & B 
(SEB/A–List Biologicals) at 250 ng ml−1. After stimulation, cells were washed and 
stained for cell surface antigens with the following combination of mAbs: anti-
CD3 Alexa700 (clone SP34-2, cat. no. 557917), anti-CD95 BB515 (clone DX2, cat. 
no. 564596) and anti-CD4 BV711 (clone L200, cat. no. 563913) (BD Biosciences); 
anti-CD8 PerCP-Cy5.5 (clone RPA-T8/SK1, cat. no. 344710) and anti-PD-1 BV421 
(clone EH12, cat.no. 329920) (Biolegend); Live/Dead Amine Aqua Dye (cat. no.  
L34966) (Life Technologies). To detect intracellular expression of cytokines, 
mononuclear cells were fixed and permeabilized with a Cytofix/Cytoperm kit  
(BD Biosciences) and stained as follows: anti-TNF-α BV650 (clone Mab11, cat. no. 
563418) and anti-IL-2 PE (clone MQ1-17H12, cat. no. 500307) (Biolegend) and 
anti-IFN-γ PE-CF594 (clone B27, cat. no. 562392) (BD Biosciences). All mAbs 
were used at the manufacturer’s recommended test volume (1:100 dilution). The 
frequency of SIV-specific memory CD4+ and CD8+ T cells producing single or 
multiple cytokines was determined after background subtraction. Cytokine  
co-expression data were processed using Pestle and SPICE version 6 (NIAID)50.
IPDA. From LN biopsy-derived, cryo-preserved mononuclear cells, CD4+ cells 
were isolated using non-human primate CD4 Microbeads (Miltenyi Biotec) and 
genomic DNA was extracted with a QIAamp DNA Mini Kit (QIAGEN). The IPDA 
was performed as described in refs. 26,51, with modifications. As the SIV IPDA was 
originally designed for SIVmac251, we adjusted the reverse primer for env to match 
measurements, multiple comparisons with Dunnett’s or Bonferroni’s correction 
for simple effects within rows relative to control or within columns relative 
to treatment baseline and P values are reported as a multiplicity between the 
directions of comparison. Cross-sectional comparisons of parameters at a solitary 
time point were calculated using either a Mann–Whitney U test, Wilcoxon rank-
sum test or a Kruskal–Wallis test with Dunn’s correction for multiple comparisons. 
Pie chart distributions were analyzed using a permutation test (10,000 iterations) 
in SPICE version 6. SIV-DNA and SIV-RNA measurements were excluded for 
samples if fewer than 10,000 cells were sorted and values fell outside the assay limit 
of detection. IPDA data were excluded if they had a DNA shearing index of >25. 
Analyses were conducted using GraphPad Prism 8.1.2.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the 
corresponding author on reasonable request. Sequences of gp160 env are available 
in GenBank (accession nos. MN856887–MN857133).
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the SIVmac239 consensus sequence: 5′-GTTGTTATTGATTTTGTCAATCCC-3′ 
(NCBI GenBank, accession no. M33262). Eight replicate wells of 500 ng DNA 
each were combined with 2× ddPCR Supermix for Probes (no dUTP, Bio-Rad) 
and primer/probe sets for regions in pol and env that favors amplification of 
intact proviral genomes. In addition, eight replicate wells of 500 ng DNA each 
were combined with ddPCR Supermix and primer/probe sets for 2-LTR circles 
and intact env, as described. Droplets were generated on the Automated Droplet 
Generator (Bio-Rad) and subsequently underwent thermocycling for 10 min at 
95 °C for 45 cycles (30 s at 94 °C and 60 s at 57 °C per cycle) and 10 min at 98 °C. 
Droplets were read on the QX100 Droplet Reader (Bio-Rad). Replicate wells were 
merged and analyzed in the QuantaSoft Analysis Pro Software. As described 
by Bender and others, a correction for shearing was not applied given low and 
similar shearing rates across samples, and the frequency of 2-LTR+env+ circles 
was subtracted from the frequency of intact (pol+env+) proviruses26,52. Samples 
with a DNA shearing index >25 were excluded from analyses (RWs16 at d−29 
p.t.; Extended Data Fig. 7c), and limited cell numbers prevented analyses in three 
control and one BsAb-treated RMs.
Genome sequencing. Single-genome sequencing of gp160 env sequences were 
generated as previously described53. Briefly, plasma was centrifuged, vRNA was 
extracted using the EZ1 Virus Mini Kit v2.0 (Qiagen) and cDNA was synthesized 
using reverse primer SHIV.Env.R1 (5′-TACCCCTACCAAGTCATCA-3′) and used 
for limiting-dilution nested PCR. Amplicons of the correct size were sequenced 
using the MiSeq platform (Illumina). Raw reads were aligned to the SIVmac239 
reference using Geneious version R11. Sequences with evidence of mixed templates 
were excluded from further analysis. Maximum-likelihood phylogenetic trees 
were generated using the HKY85 substitution model and a transition/transversion 
ratio of four in PhyML Version 3.0 (ATGC Bioinformatics) and visualized 
in FigTree54. Lineages were deemed distinct if they differed at three or more 
nucleotide positions over env. Sequences are available in GenBank (accession nos. 
MN856887–MN857133).
Sequencing was performed on plasma from chronic infection before ART 
initiation (d52 p.i.; n = 2), during on-ART, ICB-mediated viral reactivation (n = 8) 
and immediately following ATI (n = 8). A total of 248 sequences (median 13 per 
sample) were obtained. During chronic infection (d52 p.i.) RTj16 and RZl16 had a 
maximum divergence from the SIVmac239 inoculum strain of 6 and 8 nucleotides 
(0.2–0.3%) and a maximum diversity of 9 and 13 nucleotides (0.3–0.5%), 
respectively. This degree of diversity enables enumeration of virus lineages, which 
provides a minimum estimate of the number of infected cells contributing to 
plasma viremia during ICB reactivation and rebound post-ATI.
CellTrace proliferation tracking. Cryo-preserved PBMCs were thawed, rested 
overnight and washed with PBS. Cells were labeled with 5 μM CellTrace Violet (cat. 
no. C34557, Thermo Fisher Scientific) in PBS at 37 °C in a dark water bath and 
quenched for 5 min over ice in the presence of 10% FBS (Gemini Bio-products). 
CellTrace-labeled PBMCs were washed and resuspended (2.5 × 106 cells per ml) 
in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 100 U ml−1 
penicillin, 100 μg ml−1 streptomycin, 20 U ml−1 recombinant human IL-2 (Gemini 
Bio-products), 5 μg ml−1 anti-CD28-BUV737 (clone CD28.2, cat.no. 612815, BD 
Biosciences) and 5 μg ml−1 anti-CD2 (clone RPA-2.10, cat. no. 300202, Biolegend). 
Cells were plated on anti-CD3- (clone SP34-2, cat. no. 551916, BD Biosciences; 
1 μg per well) coated 96-well polystyrene plates and incubated at 37 °C with 5% 
CO2 over water. Stimulated cells were with fed with fresh medium supplemented 
with 20 U ml−1 IL-2 (final concentration) at d3 and were harvested at d6. After 
stimulation, cells were washed and stained with the following combination of 
monoclonal antibodies: anti-CD3-BUV395 (clone SP34-2, cat. no. 564117),  
anti-CD8-BUV496 (clone RPA-T8, cat. no. 612942), anti-Ki-67-AL700  
(clone B56, cat. no. 561277), anti-CD95-PE-Cy5 (clone DX2, cat. no. 559773),  
anti-CCR7-PE-Cy7 (clone 3D12, cat. no. 557648) and anti-CD28-BUV737  
(clone CD28.2, cat. no. 612815) (BD Biosciences); anti-CD4-PerCP-Cy5.5  
(clone OKT4, cat. no. 317428), anti-PD-1-BV786 (clone EH12.2H7, cat. no 
329930) and anti-CTLA-4-PE (clone BNI3, cat. no. 369604) (Biolegend); LIVE/
DEAD Fixable Near-IR Dead Cell Stain (cat. no. L34976) (Thermo Fisher 
Scientific). All mAbs were used at the manufacturer’s recommended test volume 
(1:100 dilution) per 106 cells unless otherwise noted. Samples were collected on a 
FACSymphony system (BD Biosciences) and proliferation curves were analyzed in 
FlowJo (version 9.9.6, TreeStar).
Statistical analysis. All statistical tests were two-sided and P values ≤ 0.05 (95% 
confidence interval) were considered statistically significant for each of the specific 
statistical comparisons (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Data 
showing continuous outcomes are represented as mean ± s.e.m. All measurements 
were taken from distinct samples with the exception of IFN-γ ELISpot (three 
replicates), IPDA (eight replicates) and cell-associated SIV-DNA/RNA (12 
replicates). Gaussian distribution conformity was tested using the D’Agostino–
Pearson omnibus normality test. Correlations were performed using a Pearson 
correlation coefficient. A two-way ANOVA, or a mixed-effects model if data points 
were absent, was utilized to calculate significance for longitudinal, treatment-
stratified datasets. All two-way ANOVAs employed row stacking for repeated 
publication does not necessarily reflect the views or policies of the Department of 
Health and Human Services, nor does mention of trade names, commercial products or 
organizations imply endorsement by the US Government.
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Extended Data Fig. 1 | Plasma viral loads during acute SIV infection and subsequent decay during ART. Viral loads (SIVmac239 RNA copies/mL) were 
quantified in plasma utilizing RT-qPCR and represented on a logarithmic scale. The terminal measurement (indicated in light red) for each animal indicates 
the start of ICB therapy (d0 p.t.). Initiation of ICB therapy was dependent on duration of undetectable viremia in plasma. Data sets are grouped based on 
ICB treatment as follows: (a) VHDUM (control; n=6), black; (b) anti-CTLA-4 mAb (αCTLA-4; n=6), blue; (c) anti-PD-1 mAb (αPD-1; n=6), pink;  
(d) anti-CTLA-4 plus anti-PD-1 mAb (combined blockade; n=7), red; and (e) anti-CTLA-4/PD-1 mAbdAb (BsAb; n=8), purple. Individual RMs are 
indicated by shape with closed data points indicating viral reactivation in plasma during subsequent ICB. The vertical dotted line indicates ART initiation 
(d60 p.i.) and the shaded gray area represents ongoing ART administration. The horizontal dotted line indicates the assay’s limit of detection (≤60 copies/
mL) with undetectable events represented as 30 copies/mL.
Extended Data Fig. 2 | Macaque characteristics and ICB antibodies. aAge in months at SIV infection (d0 p.i.; post-infection) and at ICB (d0 p.t.; post-
treatment). bIndicates the number of CD4+ T cells per μL of PB at chronic infection prior to ART initiation (d52 p.i.) as determined by complete blood 
counts combined with flow cytometry. cSIV-RNA viral loads per mL of plasma was measured by quantitative RT-qPCR with a limit of detection of ≤60 
copies/mL at acute (d14 p.i) and chronic infection (d52 p.i.). dDays of undetectable (UD) viral load prior to ICB treatment were calculated from the first 
UD observation following ART initiation and does not account for subsequent blips. eIndicates whether Fc gamma receptor has been disabled by a LAGA 
mutation (L235A and G237A) and is capable of antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), ect. 
fIndicates the pharmacological generic equivalent of the variable domain and epitope specificity.
Extended Data Fig. 3 | Blockade pharmacokinetics and emergence of anti-drug antibodies. (a) Plasma concentrations (ng/mL) of Co-IR blocking 
monoclonal antibodies (mAb) were quantified with an antibody capture assay; stratified by treatment group; and represented on a logarithmic scale. 
Blood was drawn immediately prior to- and 5 mins following ICB administration. (b) Using only blood drawn prior to ICB infusion, the levels of anti-drug 
antibodies (ECL, electrochemiluminescence) were quantified by MSD assay, which were utilized to calculate the percentage of inhibition. Vertical arrows 
and dotted lines represent either an ICB infusion or ART interruption, as indicated, with the gray shaded area representing ongoing ART. Individual RMs are 
indicated by shape with closed data points indicating animals with viral reactivation in plasma.
Extended Data Fig. 4 | Combined blockade leads to a limited restoration of cytolytic functionality in ICR-expressing CD8+ T cell subsets. By flow 
cytometry, the frequencies of granzyme B+ cells were determined within (a) CTLA-4+PD-1+ and (b) CTLA-4+PD-1- memory CD8+ T cells in LN following 
the fourth ICB infusion (d28 p.t.). All RMs are color-coded and grouped based on ICB therapy with population sizes as indicated for all analyses: controls 
(n=6), black; αCTLA-4 (n=6), blue; αPD-1 (n=6), pink; combined blockade (n=7), red; and BsAb (n=8), purple. Averaged data are presented as the mean 
± s.e.m. and were analyzed with a two-sided Kruskal-Wallis test with Dunn’s correction for multiple comparisons relative to controls.
Extended Data Fig. 5 | SIV-specific CD8+ T cells display an exhausted phenotype that is not rescued by ICB during suppressive ART, but by viral 
rebound following ATI. Within memory CD8+ T cells at the on-ART, pretreatment baseline (d-29 p.t.; n=5 ICB-treated, Mamu-A*01+ RMs) the frequencies 
of exhaustion, proliferative and activation biomarkers (as indicated above) were quantified via flow cytometry in SIV-specific and non-specific subsets, as 
assessed by anti-Gag-CM9 staining (as indicated below) in (a) LN and (b) PBMCs. Likewise, within LN SIV-specific memory CD8+ T cells the frequencies 
of (c) Ki-67+, (d) HLA-DR+CD38+, (e) T-bet+, and (f) Granzyme B+ cells were measured at the pre-ICB baseline and following the fourth ICB infusion (d28 
p.t.). Likewise, the frequencies of (g) Ki-67+, (h) HLA-DR+CD38+, (i) T-bet+, and (j) Granzyme B+ cells within SIV-specific memory CD8+ T cells in PBMCs 
were quantified at the pre-ICB baseline, following the third ICB treatment (d21 p.t.), and 15 days following ART interruption (d50 p.t.). Analyses were 
conducted in up to 6 Mamu-A*01+ RMs (g,h,i,j), of which 5 were ICB-treated (a,b,c,d,e,f). Each data point represents an individual animal, as indicated by 
shape, and those with ICB-related viral reactivation in plasma are represented as closed data points. Averaged data are presented as the mean ± s.e.m. 
and were analyzed with (a,b) a one-way, pair-wise ANOVA using a Bonferroni correction for multiple corrections.
Extended Data Fig. 6 | SIV-specific CD8+ T cell responses are not enhanced by blockade of PD-1 and/or CTLA-4 during long-term ART. In 5 Mamu-A*01+, 
ICB-treated RMs, the frequency of SIV-specific cells, as determined via anti-Gag-CM9 tetramer staining with flow cytometry, were measured in (a) LN and 
(b) PBMC memory CD8+ T cells at treatment baseline (d-29 p.t.) and following ICB (d21 or 28 p.t.). The number of interferon gamma (IFN-γ) spot forming 
units (SFU) per 106 mononuclear cells were quantified by ELISpot upon SIV-Gag stimulation in (c) PBMCs as a fold-change (d21 p.t. relative to d-29 p.t.) 
and (d) cross-sectionally in LN (d21 p.t). Points represent unique animals, as indicated by shape and fill, as an average of three replicates with DMSO 
background subtracted. All RMs are color-coded and grouped based on ICB therapy as follows with population sizes as indicated for all ELISpot analyses: 
controls (n=6), black; αCTLA-4 (n=6), blue; αPD-1 (n=5), pink; combined blockade (n=7), red; and BsAb (n=8), purple. From ex vivo SIV-Gag-stimulated 
PBMCs with unstimulated background subtracted, the distribution of cytokine co-expression was determined via flow cytometry in memory (e) CD4+ and 
(f) CD8+ T cells before (d-29 p.t.) and during (d21 p.t.; indicated at left) ICB administration (indicated above). Rainbow-colored inner pie wedges represent 
each Boolean combination of cytokine co-expression (annotated at far right); whereas, the stacked, outer concentric rings overlap with pie wedges that 
are positive for that cytokine (indicated at middle right): IFN-γ+, red; IL-2+, orange; TNFα+, green; and CD107a+, purple. Population sizes for all cytokine 
analyses are as follows: controls (n=6), black; αCTLA-4 (n=6), blue; αPD-1 (n=6), pink; combined blockade (n=7), red; and BsAb (n=8), purple. Averaged 
data are presented as the mean ± s.e.m., and were analyzed with a two-sided (c,d) Mann-Whitney U test or (e,f) a Permutation test.
Extended Data Fig. 7 | Combined blockade increases the ratio of cell-associated SIV-RNA relative to SIV-DNA content in PBMCs and limit intact 
provirus in LN CD4+ T cells. (a) The number of log-transformed cell-associated SIV-DNA copies per 106 PBMCs were quantified by 12 replicate reaction 
RT-qPCR prior to the first infusion (d0 p.t.), and 1 week following the first (d7 p.t.) and fourth infusions (d28 p.t.); from which (b) the ratio of SIV-RNA to 
-DNA copies was computed. All RMs are color-coded and grouped based on ICB therapy as follows with population sizes as indicated for all RT-qPCR 
analyses: controls (n=6), black; αCTLA-4 (n=6), blue; αPD-1 (n=6), pink; combined blockade (n=7), red; and BsAb (n=8), purple. By IPDA with ddPCR, 
(c) the DNA shearing index pre- and post-ICB, and (d) the fold change in intact provirus per 106 cells relative to pre-treatment baseline were quantified in 
LN CD4+ cells. For all IPDA analyses, population sizes are as follows: control (n=3), αCTLA-4 (n=6), αPD-1 (n=5), combined blockade (n=7), and BsAb 
(n=7). (e) An example IPDA plot is given for the amplification of the env relative response element (RRE) on VIC dye against pol on FAM dye in relative 
fluorescence units (RFU). A positivity cutoff of 1250 is used for env and 2000 for pol. Sample plots shown (as indicated in red) are as follows: negative 
control, merged analysis from no-template control and PBMCs at pre-infection from RLt16; env positive control, env gBlock (IDT); pol positive control, 
pol gBlock (IDT); and IPDA (shown are LN CD4+ cells at d-29 p.t. from RWs16; 1 of 58 image sets of 8 replicate reactions). Averaged data are presented 
as the mean ± s.e.m. Each data point represents an individual animal, as indicated by shape, and those with ICB-related viral reactivation in plasma are 
represented as closed data points. Data were analyzed with a two-sided (a,b) Wilcoxon matched-pairs signed rank test, (d) a Mann-Whitney U test, or (c) 
a two-way ANOVA with Bonferroni’s correction for multiple comparisons relative to baseline and controls.
Extended Data Fig. 8 | ICB does not differentially impact viral reservoir content between lymphoid and myeloid lineages, and vDNA content correlates 
with intact proviral genomes. (a) The number of LN vRNA+ cells per 105 cells were quantified by RNAscope before (d-29) and after ICB therapy (d28 p.t.).  
All RMs are color-coded and grouped based on ICB therapy as follows with population sizes as indicated for RNAscope analyses: controls (n=6), black; 
αCTLA-4 (n=6), blue; αPD-1 (n=6), pink; combined blockade (n=7), red; and BsAb (n=8), purple. In the LN B cell follicle (BCF) and T cell zone (TCZ), the 
number of (b) vDNA or (c) vRNA cells per 105 cells were measured based on their co-expression of CD3 (lymphoid) or CD68/CD163 (MØ; myeloid) in 
a subset of ICB-responsive RMs (n=19). (d) In situ immunofluorescence staining for CD3 (green), CD68/CD163 (blue), and DAPI (grey) combined with 
hybridization for SIV vDNA (red) in LN TCZ or BCF (annotated at upper right) prior to or following ICB in representative RMs (3 of 38 unique samples; 
up to two tissue sections were analyzed). vDNA positive cells are annotated with a white arrow and successive magnification within the indicated 
boxed area (white) are shown below. (e) From LN at d28 p.t., the log-transformed frequency of vDNA+ cells per 106 cells were correlated against the 
contemporaneous frequency of log-transformed intact proviral genomes per 106 CD4+ cells (n=29). Averaged data are presented as the mean ± s.e.m. 
and were analyzed with (a,b,c) a two-sided Wilcoxon matched-pairs signed rank test relative to baseline or (e) a Pearson correlation coefficient.
Extended Data Fig. 9 | Dual CTLA-4/PD-1 blockade does not control or delay viral rebound after ATI. The delay in viral rebound by ICB was  
analyzed as the average number of days until detectable viral loads were observed in plasma with RT-qPCR. Plasma viral loads following ATI are shown for 
individual RMs by ICB: (b) control, (c) αCTLA-4, (d) αPD-1, (e) combined blockade, and (f) BsAb. Mamu-A*01+ RMs are shown with a bold  
connecting line and animals with prior ICB-related viral reactivation in plasma are represented as closed data points. The dotted horizontal line indicates 
the PCR assay limit of detection, with undetectable events plotted as 30 copies/mL. (g) Plasma viral loads following ATI were averaged by ICB and are 
shown with the mean as the solid line in bold and the s.e.m. represented by the color-matched shaded region. (h) The attenuation in set-point plasma 
viremia was analyzed between chronic infection (d52 p.i.) and following rebound (d170 post-ATI, p.A.). Population sizes are as follows for all viral load  
and rebound delay analyses: controls (n=6), black; αCTLA-4 (n=6), blue; αPD-1 (n=6), pink; combined blockade (n=7), red; and BsAb (n=8), purple.  
(i) By 12 replicate reaction RT-qPCR, the number of cell-associated SIV-RNA copies per 106 cells was quantified in axillary LN at necropsy: controls (n=6), 
αCTLA-4 (n=6), αPD-1 (n=5), combined blockade (n=6), and BsAb (n=7). Averaged data are presented as the mean ± s.e.m., and were analyzed with a 
two-sided (g) two-way ANOVA with Dunnett’s correction for multiple comparisons or (a,h,i) a Mann-Whitney U test and/or Wilcoxon ranked sign test. 
Color-coded statistical asterisks indicate significance between control animals and the treatment group of that color. *, p<0.05; **, p<0.01; ***,  
p<0.001; ****, p<0.0001.
Extended Data Fig. 10 | Phylogenetic trees of gp160 env sequences from plasma. Single genome sequencing-derived gp160 env sequences from the 
plasma of 9 RMs are displayed in maximum-likelihood phylogenetic trees. Virus obtained from different experimental phases are as follows: blue, 
SIVmac239 inoculum; black, chronic infection prior to ART initiation (d52 p.i.); red, during on-ART ICB-mediated reactivation (d7-28 p.t.); and green, during 
acute rebound post-ATI. A scale bar indicating diversity for each phylogenetic tree is indicated below and lineage determinations are annotated for RUm16 
(at right). Lineages were deemed distinct if they differed at 3 or more nucleotide positions over env.
